Advertisement

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

  1. Tim Heise, MD,
  2. Christian Weyer, MD,
  3. Andreas Serwas, MD,
  4. Sebastian Heinrichs, MD,
  5. Johannes Osinga, MD,
  6. Paris Roach, MD,
  7. Jim Woodworth, PHD,
  8. Uwe Gudat, MD and
  9. Lutz Heinemann, PHD
  1. Department of Metabolic Diseases and Nutrition, World Health Organization Collaborating Center for Diabetes, Heinrich-Heine-University of Düsseldorf Düsseldorf
  2. Lilly Deutschland Bad Homburg, Germany
  3. Eli Lilly Indianapolis, Indiana
  1. Address correspondence and reprint requests to Lutz Heinemann, PhD, Klinik für Stoffwechselkrankheiten und Ernährung, Med. Einrichtungen der Heinrich-Heine-Universität, P.O. Box 101007, 40001 Düsseldorf, Germany. E-mail: lutz.heinemann{at}uni-duesseldorf.de.

Abstract

OBJECTIVE To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin.

RESEARCH DESIGN AND METHODS In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 ± 2 years (mean ± SD), whose BM1 was 23.0 ± 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid-mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration.

RESULTS Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early halfmaximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after injection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern.

CONCLUSIONS This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.

  • Received July 15, 1997.
  • Revision received January 15, 1998.
  • Accepted January 15, 1998.
| Table of Contents
Advertisement